CPRX - Catalyst Pharmaceuticals, Inc.
| Previous Close | 4.0200 |
| Open | 4.0100 |
| Bid | 0.0000 x 1000 |
| Ask | 0.0000 x 1400 |
| Day's Range | 4.0100 - 4.3100 |
| 52 Week Range | 1.8500 - 4.3100 |
| Volume | 2,644,653 |
| Avg. Volume | 1,142,465 |
| Market Cap | 427.394M |
| Beta (3Y Monthly) | 2.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2490 |
| Earnings Date | Aug 7, 2018 - Aug 13, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.33 |
- Thomson Reuters StreetEvents•2 days ago
Edited Transcript of CPRX earnings conference call or presentation 19-Mar-19 12:30pm GMT
Q4 2018 Catalyst Pharmaceuticals Inc Earnings Call
- Motley Fool•3 days ago
Why Catalyst Pharmaceuticals Stock Is Popping Today
The drugmaker's Q4 earnings release was a big hit with investors.
- Zacks•3 days ago
Catalyst (CPRX) Reports Wider Q4 Loss, Focuses on Firdapse
Catalyst (CPRX) reports wider-than-expected loss in the fourth quarter of 2018.
- Benzinga•3 days ago
The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 18) AstraZeneca plc (NYSE: AZN )(received orphan drug ...
- Associated Press•4 days ago
Catalyst: 4Q Earnings Snapshot
On a per-share basis, the Coral Gables, Florida-based company said it had a loss of 14 cents. The results did not meet Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
- GlobeNewswire•4 days ago
Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
CORAL GABLES, Fla., March 18, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.
- Simply Wall St.•8 days ago
The Catalyst Pharmaceuticals (NASDAQ:CPRX) Share Price Has Gained 181%, So Why Not Pay It Some Attention?
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But if you buy shares in aRead More...
- GlobeNewswire•11 days ago
Catalyst Pharmaceuticals to Hold Fourth Quarter Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 19th, 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that it will release fourth quarter and year end 2018 financial results after market close on Monday, March 18, 2019. Further, Catalyst management will host an investment-community conference call at 8:30 a.m. ET on Tuesday, March 19, 2019 to discuss the financial results and to provide a corporate update. A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the Investor page of the company's website at www.catalystpharma.com.
- Reuters•22 days ago
U.S. Senator Sanders urges FDA to allow older versions of $375,000 drug
U.S. Senator Bernie Sanders this week urged regulators to allow pharmacies and manufacturers to resume distributing unbranded, lower-cost versions of a drug used to treat a rare neuromuscular disorder, according to a letter provided by his office to Reuters. The drug is now sold at a list price of $375,000 a year by Catalyst Pharmaceuticals Inc under the brand name Firdapse. The company received Food and Drug Administration approval for Firdapse in November, along with rights to sell it exclusively for several years under a designation granted to developers of treatments for rare diseases.
- GlobeNewswire•22 days ago
Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2019
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support of Rare Disease Day 2019. Taking place today, Rare Disease Day involves activities worldwide to raise awareness of rare diseases and their impact on patients’ lives among the general public and decision-makers in industry and government. “We are proud to support Rare Disease Day and recognize the importance of investment in medical research that is needed to improve the lives of patients who are afflicted with rare and ultra-rare diseases,” said Patrick J. McEnany, Chairman and CEO of Catalyst.
- GlobeNewswire•24 days ago
Catalyst Pharmaceuticals Announces Publication of Phase 3 Clinical Trial Data for Firdapse® for the Treatment of Lambert-Eaton Myasthenic Syndrome
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the online publication in the Journal of Clinical Neuromuscular Disease of the results of its second Phase 3 clinical trial (LMS-003) evaluating Firdapse® (amifampridine phosphate) for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). The positive topline results from this trial were previously announced, but the full results of safety, efficacy, and other clinical data are now available online.
- Reuters•29 days ago
Catalyst Pharmaceuticals defends $375,000 drug price after Bernie Sanders rebuke
Catalyst Pharmaceuticals Inc, rebuked by U.S. Senator Bernie Sanders for its high drug prices, on Thursday defended its $375,000 treatment for a rare disease, saying the price was in line with similar products in the industry. Sanders, a vocal critic of high drug prices, had written to Florida-based Catalyst earlier this month, asking it to justify its price for Firdapse, a medication for a rare neuromuscular disease that affects about one in 100,000 people in the United States. It was also one of the campaign promises made by President Donald Trump in the 2016 elections.
- GlobeNewswire•29 days ago
Catalyst Pharmaceuticals Responds to Letter from Senator Bernie Sanders
CORAL GABLES, Fla., Feb. 21, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.
- Reuters•last month
Catalyst Pharma sees net price of drug, once free, topping $300,000
Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease, which had long been available to patients for free, will cost more than $300,000 per year including rebates to insurers and other discounts. The drug, Firdapse, is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder. U.S. Senator Bernie Sanders sent a letter to Catalyst last week asking the company to justify its pricing.
- American City Business Journals•last month
Coral Gables company under fire for drug pricing says patient care is 'top priority'
Coral Gables-based Catalyst Pharmaceuticals said patient care is its "top priority" after Sen. Bernie Sanders, I-Vermont, criticized the firm for its pricing of a medication that treats a rare autoimmune disorder. "Catalyst’s top priority is improving patient care in the [Lambert-Eaton Myasthenic Syndrome] community and potentially elsewhere within the neuromuscular community," Catalyst said in a statement provided to the South Florida Business Journal.
- GlobeNewswire•last month
Catalyst Pharmaceuticals to Present at the 21st Annual BIO CEO & Investor Conference
CORAL GABLES, Fla., Feb. 05, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.
- Reuters•2 months ago
U.S. Senator Sanders asks why drug, once free, now costs $375k
U.S. Senator Bernie Sanders sent a letter to Catalyst Pharmaceuticals on Monday asking it to justify its decision to charge $375,000 annually for a medication that for years has been available to patients for free. The drug, Firdapse, is used to treat Lambert-Eaton Myasthenic Syndrome (LEMS), a rare neuromuscular disorder, according to the letter, made available to Reuters by the senator's office. The government is intensifying its scrutiny of the pharmaceutical industry and rising prescription drug prices, a top voter concern and a priority of President Donald Trump's administration.
- Simply Wall St.•2 months ago
What Kind Of Shareholders Own Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)?
Every investor in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) should be aware of the most powerful shareholder groups. Large companies usually have institutions as shareholders, and we usually see insiders owning shares Read More...
- GlobeNewswire•3 months ago
Catalyst Pharmaceuticals Announces Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis
CORAL GABLES, Fla., Jan. 04, 2019 -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative.
- Insider Monkey•3 months ago
Should You Buy Catalyst Pharmaceuticals, Inc. (CPRX)?
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow over 700 of the best-performing investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish […]
- Simply Wall St.•3 months ago
Does Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Have A Volatile Share Price?
If you own shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) then it's worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
- GlobeNewswire•3 months ago
Report: Exploring Fundamental Drivers Behind Sabre, Catalyst Pharmaceuticals, Renewable Energy Group, Luminex, Parker Drilling, and Apollo Endosurgery — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Dec. 11, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Catalyst Pharmaceuticals Announces Conference Call to Discuss Commercialization Plan for Firdapse® (amifampridine) for Lambert-Eaton Myasthenic Syndrome (LEMS)
Catalyst Pharmaceuticals, Inc. (Catalyst) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases today announced that the company will host a conference call and webcast on December 13, 2018 at 8:30 AM ET to discuss its commercialization plan for Firdapse®, including the cost of therapy. “We look forward to providing the details of the commercial launch plan for Firdapse for the treatment of LEMS, as well as our plan for achieving our stated objective of affordable access to Firdapse for all,” said Patrick J. McEnany, Chairman and Chief Executive Officer of Catalyst Pharmaceuticals. A webcast replay will be available on the Catalyst website following the call by visiting the Investor page of the company's website at www.catalystpharma.com.
- Motley Fool•4 months ago
Why Catalyst Pharmaceuticals Stock Fell Again Today
The FDA approval of Catalyst's long-awaited LEMS drug hasn't been kind to its share price. Here's why.
